BACKGROUND: The aim of this work was to study the new bone tissue formation after bone morphogenetic protein type 2 (rhBMP-2) and P-1 application, using 5 and 10 μg of each, combined to a material carrier, in critical bone defects. METHODS: It was used 70 Wistar rats (male, ∼250 g) that were divided in 10 groups with seven animals on each. Groups are the following: critical bone defect only, pure monoolein gel, 5 μg of pure P-1, 5 μg of pure rhBMP-2, 5 μg of P-1/monoolein gel, 5 μg of rhBMP-2/monoolein gel, 10 μg of pure P-1, 10 μg of pure rhBMP-2, 10 μg of P-1/monoolein gel, 10 μg of rhBMP-2/monoolein gel. Animals were sacrificed after 4 weeks of the surgical procedure and the bone samples were submitted to histological, histomorphometrical, and immunohistochemical evaluations. RESULTS: Animals treated with pure P-1 protein, in both situations with 5 μg and 10 μg, had no significant difference (P > 0.05) for new bone formation; other groups treated with 10 μg were statistically significant (P < 0.05) among themselves and when compared with groups in which it was inserted the monoolein gel or critical bone defect only (P < 0.05). In the group involving the 10 μg rhBMP-2/monoolein gel association, it was observed an extensive bone formation, even when compared with the same treatment without the gel carrier. CONCLUSION: Using this experimental animal model, more new bone tissue was found when it was inserted the rhBMP-2, especially when this protein was combined to the vehicle, and this process seems to be dose dependent.
BACKGROUND: The aim of this work was to study the new bone tissue formation after bone morphogenetic protein type 2 (rhBMP-2) and P-1 application, using 5 and 10 μg of each, combined to a material carrier, in critical bone defects. METHODS: It was used 70 Wistar rats (male, ∼250 g) that were divided in 10 groups with seven animals on each. Groups are the following: critical bone defect only, pure monoolein gel, 5 μg of pure P-1, 5 μg of pure rhBMP-2, 5 μg of P-1/monoolein gel, 5 μg of rhBMP-2/monoolein gel, 10 μg of pure P-1, 10 μg of pure rhBMP-2, 10 μg of P-1/monoolein gel, 10 μg of rhBMP-2/monoolein gel. Animals were sacrificed after 4 weeks of the surgical procedure and the bone samples were submitted to histological, histomorphometrical, and immunohistochemical evaluations. RESULTS: Animals treated with pure P-1 protein, in both situations with 5 μg and 10 μg, had no significant difference (P > 0.05) for new bone formation; other groups treated with 10 μg were statistically significant (P < 0.05) among themselves and when compared with groups in which it was inserted the monoolein gel or critical bone defect only (P < 0.05). In the group involving the 10 μg rhBMP-2/monoolein gel association, it was observed an extensive bone formation, even when compared with the same treatment without the gel carrier. CONCLUSION: Using this experimental animal model, more new bone tissue was found when it was inserted the rhBMP-2, especially when this protein was combined to the vehicle, and this process seems to be dose dependent.
Authors: Francielly Andressa Felipetti; Victor Seabra Lima Prado Costa; Juliana Dos Santos Neves; Ingrid Grazielle Sousa; Sônia Maria De Stefano Piedade; Pedro Duarte Novaes Journal: Rev Bras Ortop (Sao Paulo) Date: 2022-01-20
Authors: Fernando José Dias; João Paulo Mardegan Issa; Mamie Mizusaki Iyomasa; Joaquim Coutinho-Netto; Ricardo Alexandre Junqueria Calzzani; Daniela Mizusaki Iyomasa; Luiz Gustavo Sousa; Sonia Regina Yokomizo de Almeida; Diego Pulzatto Cury; Ii-sei Watanabe Journal: Biomed Res Int Date: 2013-07-02 Impact factor: 3.411
Authors: Mariane Silva Pettian; Ana Maria de Guzzi Plepis; Virginia da Conceição Amaro Martins; Geovane Ribeiro Dos Santos; Clovis Antônio Lopes Pinto; Ewerton Alexandre Galdeano; Amanda Regina Alves Calegari; Carlos Alberto de Moraes; Marcelo Rodrigues da Cunha Journal: PLoS One Date: 2018-07-12 Impact factor: 3.240